医学
肺癌
免疫疗法
单克隆抗体
药品
细胞毒性T细胞
化疗
治疗指标
抗药性
靶向治疗
药物输送
药理学
抗体
肿瘤科
癌症
癌症研究
免疫学
内科学
体外
有机化学
化学
微生物学
生物
生物化学
作者
Joshua E. Reuss,Laura Gosa,Stephen V. Liu
标识
DOI:10.1016/j.cllc.2021.07.011
摘要
While both targeted therapy and immunotherapy-based strategies have emerged as frontline standard-of-care for patients with advanced lung cancer, acquired resistance and disease progression remain inevitable in most cases. Chemotherapy is a common salvage option in this scenario, but is limited by a relatively narrow therapeutic index. The emergence of antibody-drug conjugates (ADCs) offer an appealing alternative. ADCs couple the specificity of a monoclonal antibody with the cytotoxic effects of chemotherapy to facilitate the targeted delivery of cytotoxic payloads directly to cancer cells. Here, we review the general structure and function of ADCs, followed by a discussion of emerging ADCs in lung cancer and the future applications of this increasingly relevant class of novel agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI